cyclic-gmp and Hypoparathyroidism

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Adenylyl Cyclases; Animals; Cyclic AMP; Cyclic GMP; Endotoxins; Extracellular Space; Hormones; Humans; Hypercalcemia; Hypertension; Hypoparathyroidism; Kidney Diseases; Neoplasms; Nucleotides, Cyclic; Parathyroid Hormone; Protein Kinases; Pseudohypoparathyroidism; Rats

Topics: Calcium; Catecholamines; Circadian Rhythm; Clinical Trials as Topic; Cyclic AMP; Cyclic GMP; Glucagon; Humans; Hyperparathyroidism; Hypoparathyroidism; Kinetics; Methods; Nephrons; Parathyroid Hormone; Reference Values; Thyroid Gland; Vasopressins

Topics: Chromatography, Ion Exchange; Cyclic AMP; Cyclic GMP; Diabetes Insipidus; Extracellular Space; Glucagon; Humans; Hyperthyroidism; Hypoparathyroidism; Hypothyroidism; Immune Sera; Inosine Nucleotides; Iodine Radioisotopes; Methods; Nucleotides, Cyclic; Phosphorus Radioisotopes; Protein Kinases; Tritium; Vasopressins

Topics: Affective Symptoms; Animals; Asthma; Caffeine; Calcitonin; Calcium; Catecholamines; Circadian Rhythm; Cyclic AMP; Cyclic GMP; Dermatitis, Atopic; Diabetes Insipidus; Glucagon; Growth Hormone; Humans; Hypercalcemia; Hyperparathyroidism; Hypocalcemia; Hypoparathyroidism; Insulin; Organ Specificity; Parathyroid Hormone; Psoriasis; Vasopressins

Topics: Animals; Biological Transport; Creatinine; Cyclic AMP; Cyclic GMP; Escherichia coli; Extracellular Space; Glucagon; Humans; Hyperparathyroidism; Hypoparathyroidism; Kinetics; Parathyroid Hormone; Perfusion; Pseudohypoparathyroidism; Vasopressins

Topics: Calcium; Catecholamines; Circadian Rhythm; Clinical Trials as Topic; Cyclic AMP; Cyclic GMP; Glucagon; Humans; Hyperparathyroidism; Hypoparathyroidism; Kinetics; Methods; Nephrons; Parathyroid Hormone; Reference Values; Thyroid Gland; Vasopressins

To determine whether calcium modulates the action of PTH, we measured the cyclic nucleotide and phosphaturic response to PTH following a 4-h infusion of glucose (day 1) and calcium (day 2). The 12 subjects were selected to provide a range of low, normal, and high endogenous PTH function. PTH stimulated nephrogenous cAMP [185 +/- 31 nmol/100 ml glomerular filtrate (GF)], cyclic guanosine monophosphate (0.44 +/- 0.09 mumol/g creatinine), and phosphate (367 +/- 59 mg P/g creatinine) excretion. Calcium infusion stimulated nephrogenous cAMP excretion in the hypoparathyroid subjects (1.42 +/- 0.35 nmol/100 ml GF) but reduced it in subjects with normal parathyroid function (-2.22 +/- 0.46 nmol/100 ml GF). Calcium infusion stimulated cGMP (0.64 +/- 0.1 mumol/g creatinine) and phosphate (113 +/- 48 P/g creatinine) excretion in all subject groups. Calcium infusion led to a 2-fold increase in the cyclic nucleotide and phosphaturic response to PTH in the normal and hypoparathyroid subjects, but had little effect on the PTH response in hyperparathyroid subjects. The extent to which calcium potentiated the ability of PTH to stimulate nephrogenous cAMP excretion correlated negatively with the basal nephrogenous cAMP excretion (r = -0.685, P less than 0.01). We conclude that calcium potentiates the acute effects of PTH on renal cyclic nucleotide and phosphate excretion. This effect is modified by the basal levels of PTH stimulation of the kidney such that it is reduced in magnitude when basal PTH stimulation is increased.

Topics: Calcium; Cyclic AMP; Cyclic GMP; Drug Synergism; Humans; Hyperparathyroidism; Hypoparathyroidism; Kinetics; Parathyroid Hormone; Phosphates

Changes in plasma adenosine 3'5' (cAMP) and guanosine (cGMP) monophosphate, measured by specific radioimmunoassay, after 150 USP/M2 of bovine parathyroid hormone (bPTH) iv administered were studied in children with pseudohypoparathyroidism, and idiopathic hypoparathyroidism, and in normal controls. Basal concentrations of plasma cAMP (17 nmole/1 +/- 1, 6 SEM) and cGMP (8,7 nmole/1 +/- 1, 3 SEM) were the same in all studied children. Plasma cAMP in normal and idiopathic hypoparathyroid children significantly (30-fold, P less than 0.001) and constantly rose with a peak value (537 nmole/1 +/- 210 SEM) observed 5--10 min after bPTH injection. By contrast, no significant change in plasma cAMP occurred in children with pseudohypoparathyroidism. The data confirmed further the unability of pseudohypoparathyroid children to increase cAMP after exogenous PTH, while the cGMP response did not appear to be significantly modified. It is suggested that an injection of 150 USP/m2 bPTH with plasma samples for cAMP assay taken before and 10 min after hormone administration represents a simplified assessment of Ellsworth-Howard's test.

Topics: Child; Cyclic AMP; Cyclic GMP; Humans; Hypoparathyroidism; Parathyroid Hormone; Pseudohypoparathyroidism

Topics: Calcitonin; Calcium; Cyclic AMP; Cyclic GMP; Humans; Hyperparathyroidism; Hypoparathyroidism; Parathyroid Diseases; Parathyroid Hormone

Topics: Cyclic AMP; Cyclic GMP; Humans; Hyperparathyroidism; Hypoparathyroidism; Parathyroid Hormone

Topics: Adult; Caffeine; Calcitonin; Calcium; Carcinoma, Bronchogenic; Circadian Rhythm; Cyclic AMP; Cyclic GMP; Diagnosis, Differential; Humans; Hypercalcemia; Hyperparathyroidism; Hypoparathyroidism; Lung Neoplasms; Middle Aged; Osteitis Deformans; Parathyroid Glands; Parathyroid Neoplasms; Physical Exertion; Sarcoidosis